“These results are important because maintaining stable blood levels of epilepsy drugs and good control of seizures depends on people taking their medications reliably and consistently,” said study author Dean Naritoku, MD, of Southern Illinois University in Springfield and member of the American Academy of Neurology. “The more often people have to remember to take their medication each day, the more likely they are to miss a dose. Once-a-day dosing is more convenient for patients.”
The study involved 239 people from the United States and several other countries. Participants were age 13 and older with partial seizures not fully controlled by medication. Some of the participants also had secondary generalized seizures. The participants were already taking one to two epilepsy medications; lamotrigine was added to their therapy. They received either lamotrigine in an extended-release formula or placebo for 19 weeks.
Those taking lamotrigine as an added therapy had 46 percent fewer partial seizures during the study, compared to 24 percent fewer for those taking a placebo. In addition, 42 percent of those taking lamotrigine as an added therapy reduced their seizure frequently by at least half by the end of the study, compared to 24 percent of those taking a placebo.
“This new once daily medication may be an important option for people with epilepsy that could significantly increase their compliance with prescribed treatment,” said Naritoku.
The most common side effects were headache, which was experienced by 17 percent of those taking lamotrigine and 15 percent of those taking placebo, and dizziness, which was experienced by 18 percent of those taking lamotrigine and five percent of those taking placebo.
The study was sponsored and conducted by GlaxoSmithKline.
The American Academy of Neurology, an association of more than 20,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease, and multiple sclerosis.
For more information about the American Academy of Neurology, visit www.aan.com.
Angela Babb | AAN Press
WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf
First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.
The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...
Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.
Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...
A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.
Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...
02.05.2018 | Event News
13.04.2018 | Event News
12.04.2018 | Event News
18.05.2018 | Power and Electrical Engineering
18.05.2018 | Information Technology
18.05.2018 | Information Technology